Home > Publications database > The Role of SOX2 and SOX9 in Radioresistance and Tumor Recurrence. > print

001     287407
005     20241111182444.0
024 7 _ |a 10.3390/cancers16020439
|2 doi
024 7 _ |a pmid:38275880
|2 pmid
024 7 _ |a pmc:PMC10814462
|2 pmc
037 _ _ |a DKFZ-2024-00222
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Barbosa, Silvia
|0 P:(DE-He78)2677283989b003b29849ae4121bda5ff
|b 0
|e First author
245 _ _ |a The Role of SOX2 and SOX9 in Radioresistance and Tumor Recurrence.
260 _ _ |a Basel
|c 2024
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1706532237_23420
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E220#LA:E220#LA:E221#
520 _ _ |a Head and neck squamous cell carcinoma (HNSCC) exhibits considerable variability in patient outcome. It has been reported that SOX2 plays a role in proliferation, tumor growth, drug resistance, and metastasis in a variety of cancer types. Additionally, SOX9 has been implicated in immune tolerance and treatment failures. SOX2 and SOX9 induce treatment failure by a molecular mechanism that has not yet been elucidated. This study explores the inverse association of SOX2/SOX9 and their distinct expression in tumors, influencing the tumor microenvironment and radiotherapy responses. Through public RNA sequencing data, human biopsy samples, and knockdown cellular models, we explored the effects of inverted SOX2 and SOX9 expression. We found that patients expressing SOX2LowSOX9High showed decreased survival compared to SOX2HighSOX9Low. A survival analysis of patients stratified by radiotherapy and human papillomavirus brings additional clinical relevance. We identified a gene set signature comprising newly discovered candidate genes resulting from inverted SOX2/SOX9 expression. Moreover, the TGF-β pathway emerges as a significant predicted contributor to the overexpression of these candidate genes. In vitro findings reveal that silencing SOX2 enhances tumor radioresistance, while SOX9 silencing enhances radiosensitivity. These discoveries lay the groundwork for further studies on the therapeutic potential of transcription factors in optimizing HNSCC treatment.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a HNSCC
|2 Other
650 _ 7 |a HPV negative
|2 Other
650 _ 7 |a SOX2
|2 Other
650 _ 7 |a SOX9
|2 Other
650 _ 7 |a gene set signature
|2 Other
650 _ 7 |a metastasis
|2 Other
650 _ 7 |a radiation treatment
|2 Other
700 1 _ |a Laureano, Natalia Koerich
|0 0000-0002-9587-2842
|b 1
700 1 _ |a Hadiwikarta, Wahyu Wijaya
|0 P:(DE-He78)f3a873e7ab94ef36c11fcf1023c8d860
|b 2
|u dkfz
700 1 _ |a Visioli, Fernanda
|0 0000-0002-4033-8431
|b 3
700 1 _ |a Bonrouhi, Mahnaz
|0 P:(DE-He78)dfbd048cb771a09543aad8eba5013468
|b 4
|u dkfz
700 1 _ |a Pajdzik, Kinga
|b 5
700 1 _ |a Conde-Lopez, Cristina
|0 0000-0001-9928-790X
|b 6
700 1 _ |a Herold-Mende, Christel
|b 7
700 1 _ |a Eidt, Gustavo
|0 P:(DE-He78)0b3d1b5bf06d3d407258e0e93c1b515b
|b 8
700 1 _ |a Langie, Renan
|0 0000-0001-6249-2862
|b 9
700 1 _ |a Lamers, Marcelo Lazzaron
|0 0000-0001-5296-5662
|b 10
700 1 _ |a Stögbauer, Fabian
|0 0000-0002-8897-5165
|b 11
700 1 _ |a Hess, Jochen
|b 12
700 1 _ |a Kurth, Ina
|0 P:(DE-He78)f3723bca6eb95009d4c95a7590617b68
|b 13
|e Last author
|u dkfz
700 1 _ |a Jou, Adriana
|0 0000-0001-9684-3093
|b 14
|e Last author
773 _ _ |a 10.3390/cancers16020439
|g Vol. 16, no. 2, p. 439 -
|0 PERI:(DE-600)2527080-1
|n 2
|p 439
|t Cancers
|v 16
|y 2024
|x 2072-6694
856 4 _ |u https://inrepo02.dkfz.de/record/287407/files/cancers-16-00439.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/287407/files/cancers-16-00439.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:287407
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)2677283989b003b29849ae4121bda5ff
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 0000-0002-9587-2842
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)f3a873e7ab94ef36c11fcf1023c8d860
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)dfbd048cb771a09543aad8eba5013468
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 0000-0001-9928-790X
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)0b3d1b5bf06d3d407258e0e93c1b515b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 0000-0001-6249-2862
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)f3723bca6eb95009d4c95a7590617b68
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 0000-0001-9684-3093
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCERS : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-07-31T16:07:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-07-31T16:07:06Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-07-31T16:07:06Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-07-31T16:07:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-26
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-26
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCERS : 2022
|d 2023-10-26
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-26
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-26
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
915 p c |a DFG OA Publikationskosten
|2 APC
|0 PC:(DE-HGF)0002
915 p c |a DOAJ Journal
|2 APC
|0 PC:(DE-HGF)0003
920 2 _ |0 I:(DE-He78)E220-20160331
|k E220
|l E220 Radioonkologie Radiobiologie
|x 0
920 2 _ |0 I:(DE-He78)E221-20160331
|k E221
|l Molekulare Grundlagen von HNO-Tumoren
|x 1
920 1 _ |0 I:(DE-He78)E220-20160331
|k E220
|l E220 Radioonkologie Radiobiologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)E221-20160331
|k E221
|l Molekulare Grundlagen von HNO-Tumoren
|x 2
920 0 _ |0 I:(DE-He78)E220-20160331
|k E220
|l E220 Radioonkologie Radiobiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E220-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)E221-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21